Full CoverageTop news
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
By Steve Gelsi
Eli Lilly pays $1B upfront to buy gene editing partner Verve Therapeutics
By James Waldron
Eli Lilly strikes deal to buy Crispr gene-editing biotech Verve
By Oliver Barnes & Patrick Temple-West
All coverage
Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout
By Allison Gatlin
Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical
By Annalee Armstrong
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push
By Christy Santhosh & Sriparna Roy
Verve Therapeutics Stock Soars 77% After Eli Lilly’s $1.3 Billion Bid
By Elsa Ohlen & Bill Alpert
Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion
By Naomi Kresge & Gerry Smith
M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly
By Sirisha Bhogaraju
Lilly to Acquire Verve Therapeutics for Up to $1.3B
By Alex Philippidis
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
By Anubhav Mukherjee
Why Verve Therapeutics Stock Is Skyrocketing Today
By Keith Speights
Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company
By J. Edward Moreno Del Angel
Why Verve Therapeutics Stock Is Skyrocketing Today
By Keith Speights
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
By Allison Gatlin
Lilly-Verve deal sends gene editing stocks higher (LLY:NYSE)
By Dulan Lokuwithana